A Randomized, Single-Center, Observer-Blind, Vehicle- and Active Comparator-Controlled Phase 1b Study to Assess the Effect and Local Safety and Tolerability Of Roflumilast and BYK321084 – Phosphodiesterase Type 4 Inhibitors (PDE4i) Dermal Formulations in Patients with Chronic Plaque Psoriasis using a Psoriasis Plaque Test

Trial Profile

A Randomized, Single-Center, Observer-Blind, Vehicle- and Active Comparator-Controlled Phase 1b Study to Assess the Effect and Local Safety and Tolerability Of Roflumilast and BYK321084 – Phosphodiesterase Type 4 Inhibitors (PDE4i) Dermal Formulations in Patients with Chronic Plaque Psoriasis using a Psoriasis Plaque Test

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Apr 2016

At a glance

  • Drugs BYK 321084 (Primary) ; Betamethasone valerate; Calcipotriol; Roflumilast
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Sponsors Takeda Pharmaceuticals International GmbH
  • Most Recent Events

    • 01 Apr 2016 Primary endpoint of change from baseline in the thickness of psoriatic skin infiltrate after 3 weeks has been met, according to results published in the British Journal of Dermatology.
    • 01 Apr 2016 Results published in the British Journal of Dermatology
    • 01 Apr 2016 Status changed from recruiting to completed, according to results published in the British Journal of Dermatology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top